{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"6.2","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Kaplan-Meier curves will be generated for PFS. Median PFS will be estimated along with 95% confidence intervals using the method of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.\n\nPembrolizumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacogenomic Study: Correlative studies","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from enrollment until disease progression or death from any cause, assessed up to 5 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}